Results 81 to 90 of about 1,210,670 (266)
Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection
H Jafferbhoy, W Gashau, JF DillonGut Group, Biomedical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, UKAbstract: Chronic hepatitis C1 is a common cause of liver disease worldwide.
H Jafferbhoy, W Gashau, JF Dillon
doaj
Digital twins to accelerate target identification and drug development for immune‐mediated disorders
Digital twins integrate patient‐derived molecular and clinical data into personalised computational models that simulate disease mechanisms. They enable rapid identification and validation of therapeutic targets, prediction of drug responses, and prioritisation of candidate interventions.
Anna Niarakis, Philippe Moingeon
wiley +1 more source
A Review Analysis of Cost of Quality, Cost of Poor Quality, and Hidden Quality Cost
This paper aims to conduct a review analysis related to the terms cost of quality (COQ), cost of poor quality, and hidden quality cost. The analysis of publication data provides insights on understanding historical publication trends for the identification of research gaps related to hidden quality costs.
Jonathan D. Walston +3 more
openaire +2 more sources
ABSTRACT As global populations age, cancer is increasingly becoming a leading cause of morbidity and mortality among older adults, particularly in low‐ and middle‐income countries (LMICs). Despite accounting for the majority of new cancer cases and deaths, older individuals remain underrepresented in cancer research, clinical guidelines, and health ...
Ibrahim Bidemi Abdullateef +2 more
wiley +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
Assessment of new low input vine systems: Dataset on environmental, soil, biodiversity, growth, yield, disease incidence, juice and wine quality, cost and social data. [PDF]
Thiollet-Scholtus M +10 more
europepmc +1 more source
ABSTRACT Objective Peripheral neuropathies contribute to patient disability but may be diagnosed late or missed altogether due to late referral, limitation of current diagnostic methods and lack of specialized testing facilities. To address this clinical gap, we developed NeuropathAI, an interpretable deep learning–based multiclass classification ...
Chaima Ben Rabah +7 more
wiley +1 more source
ABSTRACT Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data ...
Maike Stein +7 more
wiley +1 more source
Hospital Readmission After Traumatic Brain Injury Hospitalization in Community‐Dwelling Older Adults
ABSTRACT Objective To examine the risk of hospital readmission after an index hospitalization for TBI in older adults. Methods Using data from the Atherosclerosis Risk in Communities (ARIC) study, we used propensity score matching of individuals with an index TBI‐related hospitalization to individuals with (1) non‐TBI hospitalizations (primary analysis)
Rachel Thomas +7 more
wiley +1 more source

